Views & Analysis
Oncology/ Views & Analysis/ Views and analysis
ASCO ’22 preview: Putting patients first
Jonah Comstock
asco, ASCO 2022, ASCO preview, IQVIA
0 Comment
Oncology/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis/ White Papers/ Whitepapers
The value of diverse patient representation and engagement in cancer treatment
mike.hammerton@pharmaphorum.com
cancer patients, cancer treatment, COVID-19, diversity, Envision Pharma Group, patient centricity
0 Comment
Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis
At ESMO, three studies show promise of antibody-drug conjugates in breast cancer
Jonah Comstock
asco, AstraZeneca, breast cancer, Daichii-Sankyo, ESMO, Sunil Verma
0 Comment
Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
Understanding the microbiome as an ‘overlooked critical organ’
Ben Hargreaves
drug development, gut-brain, human microbiome, immuno-oncology, pharma
0 Comment
Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
CRISPR therapies targeting the next breakthrough in oncology
Ben Hargreaves
CRISPR, US National Institutes of Health
0 Comment
Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
Cancer vaccines: providing the edge in oncology
Ben Hargreaves
cancer immunotherapy, cancer vaccines, Vaccitech
0 Comment
Oncology/ Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis
Putting patient perspectives at the heart of kidney cancer research
mike.hammerton@pharmaphorum.com
cancer, Ipsen, kidney cancer, patients, R&D, renal cell carcinoma, RWE
0 Comment
Digital/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis
AI providing the edge against cancer?
mike.hammerton@pharmaphorum.com
AI, AION, cancer diagnosis, clinical trials
0 Comment